{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/VOR/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-15T10:12:29.325Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":7078,"canonical_name":"Vor Biopharma Inc.","cik":"0001817229","uei":null,"lei":null,"duns":null,"ticker":"VOR"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":28,"clinical":2},"count":30,"timeline":[{"ts":"2026-09-04","kind":"sec.filing","form_type":"S-3ASR","title":"S-3ASR — Vor Biopharma Inc. — 2026-09-04","url_slug":"/sec/cik-0001817229/s-3asr/0001193125-26-383721","accession_number":"0001193125-26-383721","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Vor Biopharma Inc. — 2026-08-14","url_slug":"/sec/cik-0001817229/schedule-13g-a/0001231919-26-000911","accession_number":"0001231919-26-000911","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Vor Biopharma Inc. — 2026-08-13","url_slug":"/sec/cik-0001817229/schedule-13g-a/0002088344-26-000009","accession_number":"0002088344-26-000009","importance":30},{"ts":"2026-08-11","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Vor Biopharma Inc. — 2026-08-11","url_slug":"/sec/cik-0001817229/10-q/0001193125-26-343607","accession_number":"0001193125-26-343607","importance":45},{"ts":"2026-08-07","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Vor Biopharma Inc. — 2026-08-07","url_slug":"/sec/cik-0001817229/schedule-13g-a/0000315066-26-002253","accession_number":"0000315066-26-002253","importance":30},{"ts":"2026-08-06","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Vor Biopharma Inc. — 2026-08-06","url_slug":"/sec/cik-0001817229/schedule-13g/0000315066-26-002174","accession_number":"0000315066-26-002174","importance":55},{"ts":"2026-07-30","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Vor Biopharma Inc. — 2026-07-30","url_slug":"/sec/cik-0001817229/schedule-13g/0002012383-26-003175","accession_number":"0002012383-26-003175","importance":55},{"ts":"2026-07-16","kind":"sec.insider.s","reporter":"RA CAPITAL MANAGEMENT, L.P.","title":"","shares":213,"price_per_share":19.75,"usd_value":4207,"security_title":"Common Stock","importance":35.00420675},{"ts":"2026-07-16","kind":"sec.insider.s","reporter":"RA Capital Healthcare Fund LP","title":"","shares":213,"price_per_share":19.75,"usd_value":4207,"security_title":"Common Stock","importance":35.00420675},{"ts":"2026-07-16","kind":"sec.insider.s","reporter":"Kolchinsky Peter","title":"","shares":213,"price_per_share":19.75,"usd_value":4207,"security_title":"Common Stock","importance":35.00420675},{"ts":"2026-07-16","kind":"sec.insider.s","reporter":"Shah Rajeev M.","title":"","shares":213,"price_per_share":19.75,"usd_value":4207,"security_title":"Common Stock","importance":35.00420675},{"ts":"2026-07-16","kind":"sec.insider.x","reporter":"RA CAPITAL MANAGEMENT, L.P.","title":"","shares":2100000,"price_per_share":0.002,"usd_value":4200,"security_title":"Common Stock","importance":15.0042},{"ts":"2026-07-16","kind":"sec.insider.x","reporter":"RA Capital Healthcare Fund LP","title":"","shares":2100000,"price_per_share":0.002,"usd_value":4200,"security_title":"Common Stock","importance":15.0042},{"ts":"2026-07-16","kind":"sec.insider.x","reporter":"Kolchinsky Peter","title":"","shares":2100000,"price_per_share":0.002,"usd_value":4200,"security_title":"Common Stock","importance":15.0042},{"ts":"2026-07-16","kind":"sec.insider.x","reporter":"Shah Rajeev M.","title":"","shares":2100000,"price_per_share":0.002,"usd_value":4200,"security_title":"Common Stock","importance":15.0042},{"ts":"2026-07-07","kind":"sec.filing","form_type":"8-K","title":"8-K — Vor Biopharma Inc. — 2026-07-07","url_slug":"/sec/cik-0001817229/8-k/0001193125-26-297454","accession_number":"0001193125-26-297454","importance":35},{"ts":"2026-06-12","kind":"sec.filing","form_type":"8-K","title":"8-K — Vor Biopharma Inc. — 2026-06-12","url_slug":"/sec/cik-0001817229/8-k/0001193125-26-269431","accession_number":"0001193125-26-269431","importance":35},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Vor Biopharma Inc. — 2026-06-12","url_slug":"/sec/cik-0001817229/4/0001193125-26-269994","accession_number":"0001193125-26-269994","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Vor Biopharma Inc. — 2026-06-12","url_slug":"/sec/cik-0001817229/4/0001193125-26-269999","accession_number":"0001193125-26-269999","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"8-K","title":"8-K — Vor Biopharma Inc. — 2026-06-08","url_slug":"/sec/cik-0001817229/8-k/0001193125-26-261661","accession_number":"0001193125-26-261661","importance":35},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Vor Biopharma Inc. — 2026-05-15","url_slug":"/sec/cik-0001817229/schedule-13g-a/0002088344-26-000006","accession_number":"0002088344-26-000006","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Vor Biopharma Inc. — 2026-05-13","url_slug":"/sec/cik-0001817229/10-q/0001193125-26-220689","accession_number":"0001193125-26-220689","importance":45},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"Vor Biopharma","title":"A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06456580","excerpt":"[\"Generalized Myasthenia Gravis\"]","importance":60},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Vor Biopharma","title":"Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07404865","excerpt":"[\"Primary Sjogren's Disease\"]","importance":60},{"ts":"2026-05-04","kind":"sec.filing","form_type":"CORRESP","title":"CORRESP — Vor Biopharma Inc. — 2026-05-04","url_slug":"/sec/cik-0001817229/corresp/0001193125-26-204013","accession_number":"0001193125-26-204013","importance":30},{"ts":"2026-05-01","kind":"sec.filing","form_type":"UPLOAD","title":"UPLOAD — Vor Biopharma Inc. — 2026-05-01","url_slug":"/sec/cik-0001817229/upload/0000000000-26-004483","accession_number":"0000000000-26-004483","importance":30},{"ts":"2026-04-27","kind":"sec.filing","form_type":"DEF 14A","title":"DEF 14A — Vor Biopharma Inc. — 2026-04-27","url_slug":"/sec/cik-0001817229/def-14a/0001193125-26-181883","accession_number":"0001193125-26-181883","importance":40},{"ts":"2026-04-27","kind":"sec.filing","form_type":"ARS","title":"ARS — Vor Biopharma Inc. — 2026-04-27","url_slug":"/sec/cik-0001817229/ars/0001193125-26-181895","accession_number":"0001193125-26-181895","importance":30},{"ts":"2026-04-27","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — Vor Biopharma Inc. — 2026-04-27","url_slug":"/sec/cik-0001817229/defa14a/0001193125-26-181892","accession_number":"0001193125-26-181892","importance":30},{"ts":"2026-04-27","kind":"sec.filing","form_type":"S-3","title":"S-3 — Vor Biopharma Inc. — 2026-04-27","url_slug":"/sec/cik-0001817229/s-3/0001193125-26-182106","accession_number":"0001193125-26-182106","importance":30}]}